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ABSTRACT
Choriocarcinoma is one of rare neoplasms of female reproductive organs. In the last decade only a few cases of this disease 
have been registered in Poland. The paper presents the current principles of diagnosis and treatment options for this rare 
disease based on the authors’ clinical experience (description of the case) and literature review. This paper provides basic 
information on epidemiology, FIGO classification, and also discusses the chemotherapy regimens used in the medical 
treatment of choriocarcinoma. Surgical options were also considered. 
A thematic review of the most important papers published in international journals in recent years has also been made.
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INTRODUCTION
Choriocarcinoma belongs to a group of rare gynaeco-
logical cancers, being one of the most aggressive forms 
of gestational trophoblastic disease. An increased risk of 
developing choriocarcinoma is observed in the cases of 
early or late pregnancy (< 19, > 35 years of age), in particu-
lar, among women above 40 years of age, in whose case 
the risk of molar pregnancy (hydatidiform mole) is then 
approximately 7.5-fold higher [1–3]. Complete molar preg-
nancy in the pregnancy which preceded the diagnosis of 
the gestational cancer, increase the risk of malignant tropho-
blastic tumours almost 1000-fold and seems to be the most 
significant prognostic factor. Molar pregnancy may reoccur 
in about 1% patients [2]. The risk of transformation into 
choriocarcinoma in the case of complete molar pregnancy 
is estimated to be 2–3%, whilst in the case of partial molar 
pregnancy it is regarded to equal < 0.5% [4, 5]. Gestational 
choriocarcinoma arising in the fallopian tube or corneal 
ectopic pregnancyhas been reported [6–8]. The prevalence 
of choriocarcinoma in Europe and North America is evalu-
ated to be 1/40,000 pregnancies and in 1/40 cases of molar 
pregnancy. The risk of developing this condition in women 
from South-East Asia and Japan is higher and totals 9.2 and 
3.3/40 000 pregnancies respectively [1, 9]. In Poland, an epi-
demiological analysis is difficult, given the casuistry of the 
problem. In 2002–2012, 65 cases of malignant placental 
tumours were reported (code: C58 according to ICD10) and 
they accounted for the deaths of 7 women [10].
Patients with choriocarcinoma may sometimes com-
plain about abnormal vaginal bleeding. In trophoblast-orig-
inating tumours, the metastatic foci are formed via blood 
circulatory spread in the lungs (80%), vagina (30%), brain 
(10%) and liver (10%). The lung metastases are usually 
asymptomatic, but they may also cause dyspnoea, cough, 
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haemoptysis and chest pain. The vaginal metastases are the 
cause of bleeding, often with an intensity difficult to control 
due to the rich pathological tumour vascularisation [1].
According to the anatomical classification (FIGO 2002), 
the disease in the first stage is limited solely to the uterus; 
in the second — the lesion exceeds beyond the uterus, but 
is limited to the reproductive organ; in the third one — the 
metastases are found in the lungs irrespectively of the in-
volvement of the reproductive organ; in the fourth one 
— the metastases are spread to other organs [11].
The risk factors (evaluated respectively as 0, 1, 2, 4 points) 
in the above classification, comprise age (< 40, > 40 years), 
the manner of ending the pregnancy (molar pregnancy, 
miscarriage natural timely delivery), the time span from 
the end of the pregnancy (< 4, 4–7, 7–12, > 12 months), 
β-hCG level (< 103, up to 104, up to 105, > 105), tumour size 
(0.3–5, > 5 cm), the presence of distant metastases (lungs, 
spleen/kidneys, alimentary tract, brain/liver), the number 
of metastases (0, 1–4, 5–8, > 8) and previous chemotherapy 
(monochemotherapy/polychemotherapy). On the basis of 
this classification, when the score is below 6 points, the risk 
of monochemotherapy resistance is defined as low, whilst 
above this score — as high. The choice of therapeutic regi-
men is the consequence of the analysis of the above criteria.
The treatment of choriocarcinoma is based first of all 
on chemotherapy, yet surgery and radiotherapy are also 
sometimes included. Hysterectomy in the low-risk group 
patients may shorten the time of the necessary chemo-
therapy, and this is beneficial, especially in women who 
have decided to discontinue reproduction. In the patients 
in the high risk group (with metastases), hysterectomy does 
not improve the treatment outcomes and therefore is not 
recommended [12]. Intervention surgery plays an impor-
tant role, as massive haemorrhages from the highly vascu-
larised tumour are likely to happen. The scope of surgical 
procedures may be varied. Usually it is hysterectomy, but 
one must not forget about possible bleeding from the 
metastases located in the lungs or brain. Neurosurgical 
treatment is applied also in order to decrease intracranial 
pressure [13]. Sometimes it is advisable to resect the per-
sistent metastatic foci in parenchymal organs, in particular 
when these are isolated foci.
Radiotherapy is applied in the cases of brain metasta-
ses, most frequently in a form of whole brain irradiation, 
often with intrathecal administration of methotrexate [14]. 
Multidrug chemotherapy without radiotherapy can be an al-
ternative for this subgroup of patients. Gavanie et al. retro-
spectively analyzed 21 patients with brain metastases from 
gestational trophoblastic neoplasia treated by this way and 
showed high survival rate [15]. There is no consensus on op-
timal treatment of brain metastases [16]. Radiotherapy may 
also be administered in the area of minor pelvis in order to 
treat the residua focus of the tumour [17] or a non-resectable 
tumour causing recurrent bleeding [18].
Below we discuss the treatment options in a case of 
a 35-year old woman three months after the third childbirth 
(vaginal delivery) with an intensive bleeding from the repro-
ductive organ and some cough which had been intensifed 
for a few days. The last pregnancy and childbirth — similarly 
as the previous ones — were uneventful. In the gynaeco-
logical examination a tumour was found in the minor pelvis 
(8 cm in diameter) as well as some brittle infiltration, bleed-
ing upon contact, filling almost the entire vaginal lumen, 
which, upon histopathological assessment turned out to 
be choriocarcinoma. The abdominal and pelvic CT scan re-
vealed an enlarged uterine body with polycyclic contour and 
fluid space inside the uterine cavity; the vaginal walls were 
infiltrated with tumour, whilst no pathologies were found 
in the remaining organs under examination. Head CT did 
not reveal any abnormalities, yet in the chest numerous me-
tastases were found. The baseline of β-human chorionic go-
nadotopin (β-hCG) level equaled 52776.02 U/L. With respect 
to the diagnosis of choriocarcinoma with lung metastases, 
and upon risk stratification (score: 9 points), the patient 
was qualified to chemotherapy with the EMA-CO regimen. 
After the administration of 1 course of chemotherapy, the 
patient’s condition was significantly deteriorated — she was 
referred to an intensive care unit in a serious condition and 
unconscious. At that time the findings comprised thrombo-
cytopenia, neutropenia and anaemia. After the transfusion 
of packed red blodd cells (PRBCs) and the administration 
of granulocyte colony-stimulating factor (GCSF) and leu-
covorin, as well as supportive treatment, a significant im-
provement of the patient’s general condition was obtained 
together with a decrease of β-hCG concentration to the 
level of 4041.0 U/L. After 14 days of the stabilisation of the 
patient a decision was taken to resume chemotherapy. The 
patient received three courses of chemotherapy and β-hCG 
level dropped down to 88.82 U/L. Cancer infiltration in the 
vagina was significantly reduced. In spite of the above, the 
patient suffered from a vaginal bleeding (the loss of approx. 
2000 mL). With respect to the life-threatening condition the 
patient was qualified for an urgent laparotomy. During the 
intervention bleeding to the peritoneal cavity from an in-
filtrate in the uterine wall was found, so the internal iliac 
arteries were ligated and then hysterectomy was performed. 
Full haemostasis was achieved in the pelvis and bleeding 
from an infiltrate in the vagina was brought under control. 
In post-operative course, 8 units of PRBCs and 5 units of 
fresh frozen plasma (FFP) were transfused.
The histopathological assessment of the post-operative 
specimen revealed extensive necrotic areas in the body of 
the uterus which exceeded the thickness of the uterine 
muscle and also some cancer foci in the uterine cervix and 
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adnexa and in some fragments of the vaginal wall. After 
the next two weeks from the surgery, chemotherapy was 
possible to be resumed. However, another bleeding episode 
from the flat vaginal infiltration occurred, therefore high 
dose rate (HDR) brachytherapy was carried out at the dose 
of 21 Gy in three fractions, after which the residua infiltrate 
completely regressed. After four courses of chemotherapy, 
partial regression of the lung lesions was obtained and 
β-HCG level was stabilized, yet without normalization. The 
treatment so far was regarded as potentially efficacious 
and therefore it was continued according to the EMA\CO 
regimen.
During the ninth course of therapy the β-hCG level eleva-
tion was observed and therefore the regimen was changed 
into EMA\EP. After two series the marker level was normalised 
(2.31 U/L), yet during the next course, another episode of 
β-hCG elevation was observed (17.32 U/L). Chemotherapy: 
paclitaxel + cisplatin + etoposide was then implemented. Af-
ter two courses, the PET-CT examination was performed and 
the result suggested the presence of active neoplasia in the 
vaginal stump and two active cancer foci in both lungs. The 
specimens collected from the vaginal stump revealed cho-
riocarcinoma in pathomorphological assessment. Teleradio-
therapy of the minor pelvic area was performed with a dose 
of 50 Gy in 25 fractions. After the end of irradiation, given 
an elevated level of β-hCG (62 U/L, 203 U/L) the treatment 
with paclitaxel + cisplatin was implemented with a good 
tolerance. The follow-up assessment revealed persistent 
metastases in the lungs. With regards to the young age of 
the patient and a good general condition, metastasectomy 
was performed at the Thoracic Surgery Clinic of the Colle-
gium Medicum of the Jagiellonian University in Cracow was 
performed. The histopathological assessment confirmed the 
type of the tumours (choriocarcinoma). Within the further 
chemotherapy course, a significant progression of the β-hCG 
marker occurred: 13057 U/L. With regards the aggressive 
course of the disease, the treatment was modified. An at-
tempt was made to treat the patient according to the regi-
men with cyclophosphamide + methotrexate. The patient 
did not turn out for the continuation of the treatment.
DISCUSSION AND REVIEW OF THE 
LITERATURE 
As it is seen from the published data and from the treat-
ment algorithms applicable, the treatment of choice in the 
therapy of choriocarcinoma is chemotherapy, yet surgi-
cal treatment may be necessary, especially in the cases of 
life-threatening complications, most frequently connected 
with a massive bleeding from the tumour.
More than 90% patients respond to systemic therapy. 
The prognosis is better in the cases when the disease is 
limited only to the uterus or when metastases are present 
in other locations than liver and brain, when the period from 
the last pregnancy is shorter and the baseline level of β-hCG 
upon qualification for treatment was lower. The treatment 
consists in chemotherapy with methotrexate or actinomycin 
D in mono-therapy or multi-drug regimens (e.g. EMA\CO 
with additional use of etoposide, cyclophosphamide and 
vincristine). An indication for chemotherapy is such pat-
tern of choriocarcinoma, in which chemotherapy is applied 
until the normalisation of β-hCG level plus two additional 
cycles. In the case of metastases found in the patients from 
low risk group, monotherapy is used, whereas in the case 
of resistance or high risk — multi-drug regimen (EMA\CO). 
In some cases of a high-risk disease, even 3–4 additional 
chemotherapy cycles are recommended in order to mini-
mise the risk of recurrence [19]. In the follow-up after the 
treatment of choriocarcinoma, the level of β-hCG must be 
established every 4 weeks up to 6 months post treatment, 
then every 2 months, and after 12 months up to 5 years 
after treatment — every 6 months. The proposed follow-up 
patterns after choriocarcinoma treatment differ from each 
other; some practitioners suggest even the measurement of 
β-hCG level every 6 months till end of the patient’s life [19].
In 2016 Lawrie et al., presented a systematic overview 
made on the basis of the Cochrane database: comprising 
seven randomised clinical trials (RCT) describing the treat-
ment of more than 600 patients with choriocarcinoma, in 
which the effectiveness and toxicity of methotrexate and 
actinomycin D administered in monotherapy were com-
pared. The efficacy of the treatments was comparable and 
no significant differences concerning the side effects were 
found (nausea, vomiting, diarrhoea, anaemia, neutrope-
nia, thrombocytopenia); only in the case of methotrexate, 
some lower rate of alopecia was observed. In the opinion 
of the authors, the use of actinomycin D probably allows 
for a faster primary healing in a low-risk group of women, 
whilst the rate of treatment failures seems to be lower 
than in the case of therapy based on methotrexate [20]. 
Three years earlier, another overview of the research stud-
ies evaluating the efficacy of the treatment of high-risk 
trophoblastic cancers (high-risk gestational trophoblastic 
neoplasms (GTN), > 6 points in FIGO) was made also on the 
basis of the Cochrane. The authors analysed and compared 
the CHAMOCA, MAC and EMA/CO regimens. It was found 
that the CHAMOCA multi-drug therapy (cyclophosphamide, 
hydroxy-urea, actinomycin D, methotrexate, doxorubicin, 
melphalan and vincristine) is not recommended for the 
treatment of malignant trophoblastic tumours, as it is more 
toxic and less efficient than the MAC regimen (methotrexate, 
actinomycin D, chlorambucil). Chemotherapy with EMA/CO 
regime is currently the most frequently used first line ther-
apy in the case of high risk patients, although this regimen 
was not compared with other drug combinations, such as 
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MAC, in (RCT). The authors would like to note that some 
further evaluation of the above regimens is recommended 
in well designed RCTs, yet with regards to a low number of 
such diagnoses, the trials in this area are very difficult and 
thus a multi-centre collaboration is necessary [21]. Complete 
remission with oral etoposide without any significant toxic-
ity for refractory choriocarcinoma has been reported [22].
Last year Cochrane Database published another system-
atic overview, this time evaluating the role of prophylactic 
chemotherapy applied in women with diagnosed mole 
pregnancy, as a preventive measure against the develop-
ment of trophoblastic cancers. The analysis of almost 90 pa-
pers allowed to conclude that a prophylactic chemotherapy 
may decrease the risk of progression to GTN in women with 
complete mole pregnancy, in whose case there is a high risk 
of malignant transformation, yet the current evidence for the 
benefits of this therapy is quite limited by their low quality 
and a small number of patients in the analysed trials. Pre-
ventive chemotherapy may increase drug resistance, delay 
healing and cause side effects and that is why it cannot be 
routinely recommended and used [23]. Braga et al. evalu-
ated expectant versus immediate chemotherapy following 
pathological diagnosis of gestational choriocarcinoma in 
patients with nonmetastatic disease and concluded that 
close surveillance of women with pathological diagnosis 
of nonmetastatic gestational choriocarcinoma seems to be 
a safe practice [24].
SUMMARY 
Our experience based among others of the presented 
case and world recommendations show that synchronous 
lung metastases developing three months after childbirth 
prove a very dynamic character of this carcinoma. The pres-
ence of such metastases qualified our patient discussed here 
to the group with the third stage of the disease (FIGO classi-
fication) and the risk factors analysis conducted in the above 
scale (high risk patient) provided grounds for an inclusion 
of the EMA/CO polychemotherapy. This regimen is effective 
in 80% patients who were not systemically treated before.
The therapy of the patients with choriocarcinoma is 
usually long, often it is necessary to apply a dozen chemo-
therapy cycles, which leads to an accumulation of side ef-
fects and in the majority of patients it is also necessary to 
introduce supportive therapy. As many as even 1/3 high 
risk patients develop chemo-resistance. In such a situation 
the regimen must be modified or some other treatment 
methods need to be introduced, metastasectomy or ra-
diotherapy. The decision to resume oncological treatment 
after the surgery or to modify chemotherapy regimen or 
to apply radiotherapy should be taken by an experienced 
oncogynaecologist in consultation with an interdisciplinary 
cancer board. The patients with such a rare diagnosis should 
be treated in highly specialised centres and by experienced 
specialists sothat a vast range of individualised treatment 
could be possible. 
In spite of numerous chemotherapy regimens or the 
implementation of surgical treatment and radiotherapy, 
a complete therapeutic success is still not possible in every 
case in about 10–25% cases of 2 and 3 stage patients as 
defined by FIGO. The causes for the treatment failures in our 
patient, occurring in spite of the maximum efforts to treat 
her and the use of numerous methods can be found in the 
simultaneous presence of many adverse circumstances such 
as advancement stage, chemo-resistance and life-threaten-
ing complications. Moreover, about 70% patients in whose 
case treatment was not successful, are the women in whom 
choriocarcinoma developed after the childbirth — this con-
dition was also present in the above case [5].
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